Navigation Links
EPS 301 Power Supply

ProductsEPS 301 Power Supply
Company GE Healthcare, formerly Amersham Biosciences
Item EPS 301 Power Supply
Features 
  • 300 V, 400 mA, 80 W maximum.
  • Constant voltage or constant current modes.
  • Single-unit increments in settings and read-outs for precision and reproducibility.
  • Suitable for submarine, mini-vertical, and standard vertical gel electrophoresis as well as semidry and mini-tank blotting applications.
Description Inquire
Info 

Related medicine products :

1. PowerLab/4SP
2. PowerLab/8SP
3. PowerLab/16SP
4. PowerLab/4ST
5. PowerLab 2/25
6. PowerLab 4/25
7. PowerLab 4/25T
8. OPD-Scan Refractive Power / Corneal Analyzer
9. OPD-Scan II Refractive Power / Corneal Analyzer
10. G 4.12 Powerful Ventilated Floor-Standing Centrifuge
11. CR 4.12 Powerful Refrigerated Bench-Top Centrifuge.
... microscopic documentation. The Leica DC480 digital camera ... fidelity, resolution and detail. Even with low ... to perfect images due to the integrated ... modes make this camera the best choice ...
Coolpix 5000 microscope package includes Coolpix 5000 digital camera, MDC-A relay lens, EH52 AC adapter, UR-E6 step-down adapter ring, EU-1 wired remote control unit....
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
Wright Stain Solutions...
Medicine Products:
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... physicians for outpatient surgeries for bladder cancer have led ... procedures being performed and an overall increase in cost ... a new study published early online in Cancer ... The findings indicate that some Medicare policies aimed at ...
... the risk of developing asthma after the menopause, suggests a ... Thorax . The authors base their findings on ... HRT and development of asthma symptoms every two years between ... in the French E3N study, which includes almost 100, 000 ...
... ... ‘state-of-the-art’ building , ... Vancouver, Washington (PRWEB) February 7, 2010 -- Safetec Compliance Systems, Inc. ... Washington, effective immediately. The new office is located at 7700 NE Parkway Drive, ...
... ... culture, customs, history and music will open Feb. 28th in the St. Louis Jewish Community ... St. Louis, MO ... for Purim, an annual Jewish observance. The new museum is located inside the St. Louis ...
... , , Physician Assistant Foundation, Baylor College ... , HOUSTON , Feb. 6 The ... other local partners today unveiled their unique approach to providing health ... with hopes the program could become a model for meeting similar ...
... ... lift at his practice offering plastic surgery in Phoenix . For women who are ... popularity of cosmetic enhancement with breast implants. , ... Phoenix, AZ (Vocus) February 6, 2010 -- Over the course of his ...
Cached Medicine News:Health News:Medicare reimbursement change meant to save money has opposite effect 2Health News:Estrogen-only HRT may increase risk of asthma after menopause 2Health News:Safetec Compliance Systems Announces Expansion 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 2Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 3Health News:Community Health Navigator Program to Fill Gaps in Care for Houston's Burmese Refugees 4Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 2Health News:Is Breast Augmentation Surgery Right for Me? Arizona Breast Surgeon Discusses Various Breast Procedures 3
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8